Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats

Pharmacology

Volumn 90, Issue 3-4, 2012, Pages 177-182

  Hou, Jun ^a   Zheng, Dezhi ^b   Fan, Kaihua ^a   Yu, Botao ^a   Xiao, Wenjing ^a   Ma, Jie ^a   Jin, Weihua ^a   Tan, Yonghong ^a   Wu, Juan ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Mangiferin; Sitagliptin; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; INSULIN; MANGIFERIN; SITAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MORPHOLOGY; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; INSULIN; ISLETS OF LANGERHANS; MALE; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TRIAZOLES; XANTHONES;

EID: 84865592318     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000342128     Document Type: Article

References (17)

1. Smyth S, Heron A: Diabetes an d obesity: the twin epidemics. Nat Med 2006;12:75-80.
2. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705.
3. Burkey BF, Li X, Bolognese L, et al: Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005;315:688-695.
4. Mest HJ, Mentlein R: Dipeptidyl peptidase inhibitors as new drugs for the treatment of type diabetes. Diabetologia 2005;48:616-620.
5. Deacon CF: Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs 2007;16: 533-545.
6. Sanchez GM, Re L, Giuliani A, Nunez-Selles AJ, Davison GP, Leon-Fernandez OS: Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacol Res 2000;42:565-573.
7. Guha S, Ghosal S, Chattopadhyay U: Antitumor, immunomodulatory and anti-HIV effect of mangiferin, a naturally occurring glucosyl xanthone. Chemotherapy 1996;42: 443-451.
8. Guo F, Huang C, Liao X, et al: Beneficial effects of mangiferin on hyperlipidemia in high-fat-fed hamsters. Mol Nutr Food Res 2011;55:1809-1818.
9. Muruganandan S, Srinivasan K, Gupta S, Gupta PK, Lal J: Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J Ethno Pharmacol 2005;97:497-501.
10. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK: Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 2002;176:165-173.
11. Yogisha S, Raveesha KA: Dipeptidyl peptidase IV inhibitory activity of Mangifera indica. J Nat Prod 2010;3:76-79.
12. Hou J, Zheng DZ, Zhou JY, Zhou SW: Orexigenic effect of cocaine-and amphetamineregulated transcript (CART) after injection into hypothalamic nuclei in streptozotocindiabetic rats. Clin Exp Pharmacol Physiol 2010;37:989-995.
13. Holman RR: Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism 2006;55: S2-S5.
14. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
15. Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M: Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice. Eur J Pharmacol 2009;605:170-176.
16. Yamazaki K, Inoue T, Yasuda N, et al: Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice. J Pharmacol Sci 2007;104: 29-38.
17. Niu Y, Li S, Na L, et al: Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK. PLoS One 2012;7:e30782.